Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 4/20 | 0.51 |
| ▸ | TERT | O14746 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533829 | 1.00 | SLC6A5 (0.52) | SLC6A5FAAHTERTPTPN1PPARG | |
| SCHEMBL29077348 | 1.00 | SLC6A5 (0.52) | SLC6A5FAAHTERTPTPN1PPARG | |
| Hydrochloric Acid SCHEMBL1828097 | 0.99 | SLC6A5 (0.51) | SLC6A5FAAHTERTPTPN1PPARG | |
| Bromide SCHEMBL29058708 | 0.99 | SLC6A5 (0.51) | SLC6A5FAAHTERTPTPN1PPARG | |
| Hydrochloric Acid SCHEMBL28566602 | 0.99 | SLC6A5 (0.51) | SLC6A5FAAHTERTPTPN1PPARG | |
| Hydrochloric Acid SCHEMBL1773161 | 0.99 | SLC6A5 (0.51) | SLC6A5FAAHTERTPTPN1PPARG | |
| Hydrochloric Acid SCHEMBL14060920 | 0.99 | SLC6A5 (0.51) | SLC6A5FAAHTERTPTPN1PPARG | |
| Hydrochloric Acid SCHEMBL20258167 | 0.99 | SLC6A5 (0.51) | SLC6A5FAAHTERTPTPN1PPARG | |
| SCHEMBL625634 | 0.91 | MAPK1 (0.47) | SLC6A5CYP1A2MAPTCYP2C19BLM | |
| SCHEMBL725613 | 0.91 | MAPK1 (0.47) | SLC6A5CYP1A2MAPTCYP2C19BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113924082-B | Preparation and storage of liposomal RNA formulations suitable for treatment | 生物技术公司 | 2024-07-05 | — | — | CN | claimed |
| CN-117947057-A | MRNA nano liposome particle for preventing swine fever and preparation and detection methods thereof | 中国兽医药品监察所 | 2024-04-30 | — | — | CN | claimed |
| CN-117203340-A | Optimized TLR7 ligands and uses thereof | 基因泰克公司 | 2023-12-08 | — | — | CN | claimed |
| CN-111164068-B | Biodegradable compound, lipid particle, composition containing lipid particle, and kit | 株式会社东芝 | 2023-11-14 | — | — | CN | claimed |
| CN-111939252-B | Phospholipid, cpG-ODN and cyclic dinucleotide co-modified aluminium nano vaccine adjuvant-delivery system and preparation method thereof | 安徽省力瑞投资管理有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-113710233-B | Composition, lipid particle manufacturing kit, substance delivery method and detection method | 国立大学法人信州大学 | 2023-09-26 | — | — | CN | claimed |
| CN-116782892-A | Methods and compositions comprising cationic lipids for immunotherapy by direct tumor injection | PDS生物科技公司 | 2023-09-19 | — | — | CN | claimed |
| CN-116615223-A | Layer-by-layer coated nanoliposomes for oral delivery of insulin | 南洋理工大学 | 2023-08-18 | — | — | CN | claimed |
| CN-115379826-B | Boundary surface charged contact lens for delivery | 领视药公司 | 2023-07-21 | — | — | CN | claimed |
| CN-116249525-A | Nanoparticles containing multiple cleavable prodrugs for cancer therapy | 芝加哥大学 | 2023-06-09 | — | — | CN | claimed |
| CN-116194081-A | Preparation and storage of liposomal RNA formulations suitable for treatment | 生物技术公司 | 2023-05-30 | — | — | CN | claimed |
| EP-2319519-B1 | COMPOSITION FOR INHIBITING EXPRESSION OF TARGET GENE | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-01-27 | — | — | EP | claimed |
| EP-1842558-B1 | COMPOSITION FOR INHIBITING EXPRESSION OF TARGET GENE | KYOWA HAKKO KIRIN CO LTD (JP) | 2012-06-13 | — | — | EP | claimed |
| EP-4703381-A1 | ANTIBODIES AGAINST ICAM-1 AND APPLICATIONS THEREOF | Institució Catalana de Recerca i Estudis Avançats (ES) | 2026-03-04 | — | — | EP | disclosed |
| US-20240366638-A1 | PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS | SYNAPTIVE THERAPEUTICS, LLC | 2024-11-07 | — | — | US | disclosed |
| US-20240335401-A1 | SUBSTITUTED PHENETHYLAMINE FOR TREATING INFLAMMATION AND PSYCHOLOGICAL DISORDERS | SYNAPTIVE THERAPEUTICS LLC | 2024-10-10 | — | — | US | disclosed |
| EP-2474306-A1 | PARTICLE COMPOSITION AND MEDICINAL COMPOSITION COMPRISING SAME | NanoCarrier Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120107377-A1 | PARTICULATE COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | NANOCARRIER CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-20120076866-A1 | PARTICULATE PHARMACEUTICAL COMPOSITION | NANOCARRIER CO., LTD. (JP) | 2012-03-29 | — | — | US | disclosed |
| EP-2415463-A1 | PARTICULATE MEDICINAL COMPOSITION | NanoCarrier Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076866-A1 | PARTICULATE PHARMACEUTICAL COMPOSITION | CHMP4B, PLIN3, ABCB4 | SLC6A5 4738/4885FAAH 1123/4885TERT 4478/4885 |
| US-20240335401-A1 | SUBSTITUTED PHENETHYLAMINE FOR TREATING INFLAMMATION AND PSYCHOLOGICAL DISORDERS | PNMT, HTR6, HTR2C | SLC6A5 569/4885FAAH 124/4885TERT 1863/4885 |
| US-20120107377-A1 | PARTICULATE COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CHMP4B, CETP, AUP1 | SLC6A5 3849/4885FAAH 1669/4885TERT 4680/4885 |
| US-20240366638-A1 | PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS | HTR1B, HTR2B, PNMT | SLC6A5 1090/4885FAAH 51/4885TERT 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.